Tadahiko Shien
Overview
Explore the profile of Tadahiko Shien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sagara Y, Terata K, Sakai T, Takayama S, Kitagawa D, Iwatani T, et al.
JMA J
. 2025 Feb;
8(1):264-269.
PMID: 39926095
Introduction: This prospective, multicenter, single-arm Phase II trial investigates the feasibility and the safety of tailored axillary surgery (TAS) in patients with clinically node-positive breast cancer who are undergoing upfront...
2.
Kojima R, Ishitobi M, Nagura N, Shimo A, Seki H, Ogiya A, et al.
Surg Pract Sci
. 2025 Jan;
17():100239.
PMID: 39845638
Background: Recent studies have shown that receptor status of breast cancer change between primary tumor and recurrence, which may influence treatment strategy and prognosis, but there are few reports on...
3.
Takahashi Y, Tsukioki T, Iwatani T, Shien T
Gan To Kagaku Ryoho
. 2024 Dec;
51(12):1209-1211.
PMID: 39721780
No abstract available.
4.
Mamori T, Tanioka M, Takada K, Hamano H, Tsukioki T, Takahashi Y, et al.
BioDrugs
. 2024 Oct;
39(1):131-142.
PMID: 39412713
Background: Despite the global use of trastuzumab biosimilars, concerns remain regarding their efficacy and safety. In particular, when used concurrently with pertuzumab, trastuzumab biosimilars lack extensive real-world data and safety...
5.
Nakamoto S, Waki T, Mimata A, Tsukioki T, Takahashi Y, Iwatani Y, et al.
Int Cancer Conf J
. 2024 Oct;
13(4):471-475.
PMID: 39398903
Abemaciclib (ABM) is recommended for adjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor type 2-negative early breast cancer (EBC) patients at high risk of recurrence. Here, we...
6.
Zhu Y, Nakamoto S, Tsukioki T, Takahashi Y, Iwatani Y, Iwatani T, et al.
Chin Clin Oncol
. 2024 Sep;
13(5):68.
PMID: 39260429
Background And Objective: Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better...
7.
Seki H, Sasada S, Shien T
Breast Cancer
. 2024 Sep;
31(6):1183.
PMID: 39217590
No abstract available.
8.
Iwatani T, Sasaki K, Machida R, Shien T, Hara F, Fujisawa T, et al.
Jpn J Clin Oncol
. 2024 Aug;
54(10):1093-1099.
PMID: 39178176
Background: The increasing incidence and prevalence of breast cancer alongside diagnostic and treatment technology advances have produced a debate about the financial burden cancer places on the healthcare system and...
9.
Nakamoto S, Iwamoto T, Taira N, Kajiwara Y, Kawada K, Takabatake D, et al.
Breast Cancer
. 2024 Jul;
31(5):969-978.
PMID: 38980571
Background: Although the association between higher physical activity and preventive effect on breast-cancer-related lymphoedema (BCRL) has been reported, it is unclear what intervention is optimal. We aimed to investigate the...
10.
Shien T, Tsuda H, Sasaki K, Mizusawa J, Akiyama F, Kurosumi M, et al.
Breast Cancer Res Treat
. 2024 Jun;
208(1):145-154.
PMID: 38935214
Background: In JCOG0306 trial, a phase II study to examine the efficacy of neoadjuvant chemotherapy followed by radiation therapy (NAC-RT) to primary breast cancer, pathological complete response (pCR) was evaluated...